Pegasparaginase: Where do we stand?

Expert Opinion on Biological Therapy

Volumn 9, Issue 1, 2009, Pages 111-119

  Zeidan, Amer ^a   Wang, Eunice S ^b,c   Wetzler, Meir ^b  

^a ROCHESTER GENERAL HOSPITAL   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

Author keywords

Acute lymphoblastic leukemia; Oncaspar; Pegasparaginase; Pegaspargase; Pegylation

Indexed keywords

ASPARAGINASE MACROGOL; ANTINEOPLASTIC AGENT; ASPARAGINASE; ASPARAGINE; MACROGOL DERIVATIVE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANAPHYLAXIS; ANTINEOPLASTIC ACTIVITY; ASPARAGINASE BLOOD LEVEL; BONE MARROW SUPPRESSION; CHEMISTRY; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; HALF LIFE TIME; HUMAN; HYPERBILIRUBINEMIA; HYPERSENSITIVITY REACTION; IMMUNOGENICITY; INFECTION COMPLICATION; LIVER TOXICITY; NONHUMAN; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; ANIMAL; DRUG RESISTANCE; METABOLISM;

ESCHERICHIA COLI;

ANIMALS; ANTINEOPLASTIC AGENTS; ASPARAGINASE; ASPARAGINE; CLINICAL TRIALS AS TOPIC; DRUG HYPERSENSITIVITY; DRUG RESISTANCE, NEOPLASM; HUMANS; POLYETHYLENE GLYCOLS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 58149385278     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712590802586058     Document Type: Review

References (69)

1. Mashburn LT, Wriston JC Jr. Tumor inhibitory effect of L-asparaginase from Escherichia coli. Arch Biochem Biophys 1964;105:450-452
2. Park YK, Abuchowski A, Davis S, et al. Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct. Anticancer Res 1981;1:373-376 (Pubitemid 12161043)
3. Molineux G. Pegylation: Engineering improved biopharmaceuticals for oncology. Pharmacotherapy 2003;23:S3-8
4. Keating MJ, Holmes R, Lerner S, et al. L-asparaginase and PEG asparaginase-past, present, and future. Leuk Lymphoma 1993;(10 Suppl):153-157 (Pubitemid 23120982)
5. Avramis VI, Panosyan EH. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Clin Pharmacokinet 2005;44:367-93 •• An excellent detailed review of PEG-ASP, with special emphasis on its pharmacokinetics and pharmacodynamics.
6. Apostolidou E, Swords R, Alvarado Y, et al. Treatment of acute lymphoblastic leukaemia: a new era. Drugs 2007;67:2153-2171 (Pubitemid 47557092)
7. Haskell CM, Canellos GP. L-asparaginase resistance in human leukemia -asparagine synthetase. Biochem Pharmacol 1969;18:2578-2580
8. Haskell CM, Canellos GP, Leventhal BG, et al. L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 1969;281:1028-1034
9. Haskell CM, Canellos GP. Asparaginase and leukaemia. Lancet 1969;1:626
10. Haskell CM, Canellos GP, Cooney DA, et al. Biocmical and pharmacologic effects of L-asparaginase in man. J Lab Clin Med 1970;75:763-770
11. Cooney DA, Handschumacher RE. L-asparaginase and L-asparagine metabolism. Annu Rev Pharmacol 1970;10:421-440
12. Capizzi RL, Bertino JR, Skeel RT, et al. L-asparaginase: clinical, biochemical, pharmacological, and immunological studies. Ann Intern Med 1971;74:893-901
13. Nandy P, Periclou AP, Avramis VI. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis. Anticancer Res 1998;18:727-737 (Pubitemid 28239587)
14. Fu CH, Martin-Aragon S, Weinberg KI, et al. Reversal of cytosine arabinoside (ara-C) resistance by the synergistic combination of 6-thioguanine plus ara-C plus PEG-asparaginase (TGAP) in human leukemia lines lacking or expressing p53 protein. Cancer Chemother Pharmacol 2001;48:123-133 (Pubitemid 32710223)
15. Douer D, Yampolsky H, Cohen LJ, et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood 2007;109:2744-50 • This study demonstrated the feasibility, tolerability and efficacy of IV PEG-ASP in adult patients with ALL. (Pubitemid 46482066)
16. Miller HK, Balis ME. Glutaminase activity of L-asparagine amidohydrolase. Biochem Pharmacol 1969;18:2225-2232
17. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004;26:217-226 (Pubitemid 38500969)
18. Panosyan EH, Grigoryan RS, Avramis IA, et al. Deamination of glutamine is a prerequisite for optimal asparagine deamination by asparaginases in vivo (CCG-1961). Anticancer Res 2004;24:1121-5 • This article discusses the importance of glutamine deamination in enhancing the anitleukemic effects of ASP.
19. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood 2002;99:1986-1994 (Pubitemid 34525479)
20. Ho DH, Brown NS, Yen A, et al. Clinical pharmacology of polyethylene glycol-L-asparaginase. Drug Metab Dispos 1986;14:349-352 (Pubitemid 16037445)
21. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993;11:1780-6 • Excellent review of the pharmacokinetics of the three available ASP preparations.
22. Holle LM. Pegaspargase: an alternative? Ann Pharmacother 1997;31:616-624
23. Armstrong JK, Hempel G, Koling S, et al. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 2007;110:103-111 (Pubitemid 46986423)
24. Woo MH, Hak LJ, Storm MC, et al. Cerebrospinal fluid asparagine concentrations after Escherichia coli asparaginase in children with acute lymphoblastic leukemia. J Clin Oncol 1999;17:1568-1573 (Pubitemid 29220866)
25. Riccardi R, Holcenberg JS, Glaubiger DL, et al. L-asparaginase pharmacokinetics and asparagine levels in cerebrospinal fluid of rhesus monkeys and humans. Cancer Res 1981;41:4554-4558 (Pubitemid 12201374)
26. Rizzari C, Citterio M, Zucchetti M, et al. A pharmacological study on pegylated asparaginase used in front-line treatment of children with acute lymphoblastic leukemia. Haematologica 2006;91:24-31 (Pubitemid 43235382)
27. Jayaram HN, Cooney DA, Jayaram S, et al. A simple and rapid method for the estimation of L-asparaginase in chromatographic and electrophoretic effluents: comparison with other methods. Anal Biochem 1974;59:327-346
28. Abshire TC, Pollock BH, Billett AL, et al. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 2000;96:1709-15 • This trial showed possible advantages of weekly PEG-ASP dosing compared with the standard biweekly regimen in relapsed pediatric ALL. (Pubitemid 30661053)
29. Boos J, Werber G, Ahlke E, et al. Monitoring of asparaginase activity and asparagine levels in children on different asparaginase preparations. Eur J Cancer 1996;32A:1544-1550 (Pubitemid 26279122)
30. Hawkins DS, Park JR, Thomson BG, et al. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Clin Cancer Res 2004;10:5335-5341 (Pubitemid 39100468)
31. Nesbit M, Chard R, Evans A, et al. Evaluation of intramuscular versus intravenous administration of L-asparaginase in childhood leukemia. Am J Pediatr Hematol Oncol 1979;1:9-13 (Pubitemid 11198758)
32. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982;49:1378-1383
33. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-3133
34. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002;99:2734-2739 (Pubitemid 34525359)
35. Rosen O, Muller HJ, Gokbuget N, et al. Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study. Br J Haematol 2003;123:836-841 (Pubitemid 37533295)
36. Abuchowski A, Kazo GM, Verhoest CR Jr, et al. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem Biophys 1984;7:175-186
37. Wada H, Imamura I, Sako M, et al. Antitumor enzyme: polyethylene glycol-modified asparaginase. Ann N Y Acad Sci 1990;613:95-108
38. Muss HB, Spell N, Scudiery D, et al. A Phase II trial of PEG-L-asparaginase in the treatment of non-Hodgkins lymphoma. Invest New Drugs 1990;8:125-130 (Pubitemid 20087258)
39. Kawashima K, Takeshima H, Higashi Y, et al. High efficacy of monomethoxypolyethylene glycol-conjugated L-asparaginase (PEG2-ASP) in two patients with hematological malignancies. Leuk Res 1991;15:525-530
40. Agrawal NR, Bukowski RM, Rybicki LA, et al. A Phase I-II trial of polyethylene glycol-conjugated L-asparaginase in patients with multiple myeloma. Cancer 2003;98:94-99 (Pubitemid 36741131)
41. Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist 2007;12:991-8 •• A detailed review of the trial that led to FDA approval of PEG-ASP use as a part of first line multiagent chemotherapy in pediatric ALL. (Pubitemid 47359142)
42. Ettinger LJ, Kurtzberg J, Voute PA, et al. An open-label, multicenter study of polyethylene glycol-L-asparaginase for the treatment of acute lymphoblastic leukemia. Cancer 1995;75:1176-1181
43. Muller HJ, Loning L, Horn A, et al. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols. Br J Haematol 2000;110:379-384 (Pubitemid 30646864)
44. Graham ML. Pegaspargase: a review of clinical studies. Adv Drug Deliv Rev 2003;55:1293-1302
45. Douer D, Cohen LJ, Periclou LA, et al. Peg-L-asparaginase (PEG-ASP): Pharmacokinetics (PK) and clinical response in newly diagnosed adults with acute lymphoblastic leukemia (ALL) treated with multiagent chemotherapy. Blood 1997;90(Suppl 1):334a
46. Wetzler M, Sanford BL, Kurtzberg J, et al. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood 2007;109:4164-7 •• The largest nonrandomized clinical trial to date investigating the beneficial effect of PEG-ASP in newly diagnosed adults with ALL. (Pubitemid 46743378)
47. Fu CH, Sakamoto KM. PEG-asparaginase. Expert Opin Pharmacother 2007;8:1977-1984
48. Kurre HA, Ettinger AG, Veenstra DL, et al. A pharmacoeconomic analysis of pegaspargase versus native Escherichia coli L-asparaginase for the treatment of children with standard-risk, acute lymphoblastic leukemia: the Children's Cancer Group study (CCG-(1962) J Pediatr Hematol Oncol 2002;24:175-181 (Pubitemid 34297559)
49. Peters BG, Goeckner BJ, Ponzillo JJ, et al. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment Formulary 1995;30:388-393
50. Weiss RB. Hypersensitivity reactions. Semin Oncol 1992;19:458-477
51. Killander D, Dohlwitz A, Engstedt L, et al. Hypersensitive reactions and antibody formation during L-asparaginase treatment of children and adults with acute leukemia. Cancer 1976;37:220-228
52. Larson RA, Fretzin MH, Dodge RK, et al. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia. Leukemia 1998;12:660-665 (Pubitemid 28220817)
53. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000;18:1525-1532 (Pubitemid 30205399)
54. Wacker P, Land VJ, Camitta BM, et al. Allergic reactions to E. coli L-asparaginase do not affect outcome in childhood B-precursor acute lymphoblastic leukemia: a Children's Oncology Group Study. J Pediatr Hematol Oncol 2007;29:627-632 (Pubitemid 47368000)
55. Iwamoto S, Mihara K, Downing JR, et al. Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase. J Clin Invest 2007;117:1049-57 • This article discusses a new proposed mechanism of ALL cells' resistance to ASP.
56. Williams DA. A new mechanism of leukemia drug resistance? N Engl J Med 2007;357:77-78
57. Ohnuma T, Holland JF, Freeman A, et al. Biochemical and pharmacological studies with asparaginase in man. Cancer Res 1970;30:2297-2305
58. Cheung NK, Chau IY, Coccia PF. Antibody response to Escherichia coli L-asparaginase. Prognostic significance and clinical utility of antibody measurement. Am J Pediatr Hematol Oncol 1986;8:99-104 (Pubitemid 16092149)
59. Oettgen HF, Stephenson PA, Schwartz MK, et al. Toxicity of E. coli. L-asparaginase in man. Cancer 1970;25:253-278
60. Stams WA, den Boer ML, Holleman A, et al. Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia. Blood 2005;105:4223-4225 (Pubitemid 40720766)
61. Su N, Pan YX, Zhou M, et al. Correlation between asparaginase sensitivity and asparagine synthetase protein content, but not mRNA, in acute lymphoblastic leukemia cell lines. Pediatr Blood Cancer 2008;50:274-279
62. Kaspers GJ, Smets LA, Pieters R, et al. Favorable prognosis of hyperdiploid common acute lymphoblastic leukemia may be explained by sensitivity to antimetabolites and other drugs: results of an in vitro study. Blood 1995;85:751-756
63. Ramakers-van Woerden NL, Pieters R, Loonen AH, et al. TEL/AML1 gene fusion is related to in vitro drug sensitivity for L-asparaginase in childhood acute lymphoblastic leukemia. Blood 2000;96:1094-1099 (Pubitemid 30616878)
64. Stams WA, den Boer ML, Beverloo HB, et al. Sensitivity to L-asparaginase is not associated with expression levels of asparagine synthetase in t(12;21)+ pediatric ALL. Blood 2003;101:2743-2747 (Pubitemid 36857638)
65. Appel IM, Kazemier KM, Boos J, et al. Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study. Leukemia 2008;22:1665-1679
66. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood 2001;97:1211-8 •• This is the largest randomized trial of PEG-ASP in children. (Pubitemid 32183741)
67. Cortes J, O'Brien SM, Pierce S, et al. The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 1995;86:2091-2097
68. Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008;26:1932-1939
69. Tardito S, Uggeri J, Bozzetti C, et al. The inhibition of glutamine synthetase sensitizes human sarcoma cells to L-asparaginase. Cancer Chemother Pharmacol 2007;60:751-758 (Pubitemid 47247286)